Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 23, 2024
Product Development
Rescuing stroke drug development: How NIH is leading the charge
The first graduate of the institute’s preclinical stroke study is gearing up to enter its new clinical platform
BioCentury | Sep 19, 2024
Discovery & Translation
A multisite preclinical study brings rigor to stroke research. Is the model generalizable?
High-quality, reproducible preclinical science is feasible, says USC Keck School’s Patrick Lyden: a BioCentury Q&A
BioCentury | Sep 27, 2023
Discovery & Translation
Targeting ACSS2 in solid tumors; plus a multi-lab preclinical trial and more
BioCentury’s roundup of translational innovation
BioCentury | Jun 21, 2021
Deals
Horizon pads gout pipeline with deal for Arrowhead’s siRNA therapy
Months after broadening its pipeline via the $3 billion-plus takeout of Viela, Horizon is adding to its gout franchise through a smaller deal with Arrowhead for a preclinical siRNA therapeutic.
BioCentury | Aug 9, 2019
Clinical News
Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert
BioCentury | Jun 14, 2019
Clinical News
June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more
Items per page:
1 - 10 of 171